PTK2 and neoplasm: Very importantly, the tumor microenvironment, namely melanoma associated fibroblasts, were activated by BRAF inhibition inducing FAK-dependent melanoma survival and a combination of Vemurafenib with a FAK inhibitor lead to tumor regression in mouse allografts and patient-derived xenografts [52].